Avastin Hearing's Deadline For Written Submissions Is Indefinitely Delayed
This article was originally published in The Pink Sheet Daily
Executive Summary
Presiding Officer Karen Midthun postpones the submission deadline for written summaries of arguments by Genentech and CDER until one week after the formal hearing notice is issued, although it remains unclear when that will occur.
You may also be interested in...
CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing
FDA's Center for Drug Evaluation and Research says its discussions with Genentech about a proposed confirmatory trial in metastatic breast cancer are irrelevant to the withdrawal of bevacizumab's accelerated approval for the indication.
CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing
FDA's Center for Drug Evaluation and Research says its discussions with Genentech about a proposed confirmatory trial in metastatic breast cancer are irrelevant to the withdrawal of bevacizumab's accelerated approval for the indication.
An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial
Even if the commissioner determines the grounds for withdrawing Avastin's accelerated approval in breast cancer have been met, she could decide to retain the claim while Genentech conducts additional confirmatory trials, the hearing notice explains.